A

Avalo Therapeutics

Develops IL-1beta-targeting biologics for inflammation

Medical Director / Senior Medical Director - Clinical Development-Rheumatology

Biology & BiotechConfirmed live in the last 24 hours
Full-timeChesterbrook, PA, USANo salary listedIn-person

About the Job

Requirements

  • An MD or equivalent medical degree is required.
  • A background or therapeutic experience in rheumatology, immunology, autoimmune disease, or related inflammatory conditions is required.
  • At least 5 years of biotechnology, pharmaceutical, academic medicine, clinical research, or related clinical development experience is required.
  • Direct clinical experience supporting or leading late-stage phase 2/3 drug-development studies is required.
  • A strong understanding of early clinical development, dose-escalation methodologies, safety monitoring, and translational medicine principles is required.
  • Experience reviewing and interpreting clinical safety, efficacy, pharmacokinetic/pharmacodynamic, and biomarker data is required.

Responsibilities

  • Provide medical leadership and oversight for assigned clinical programs.
  • Contribute to early clinical-development strategy, including dose selection, clinical-trial design, safety monitoring, biomarker strategy, and proof-of-mechanism approaches.
  • Support the design, review, and execution of clinical protocols, investigator brochures, informed consent forms, clinical study reports, and regulatory documents in compliance with clinical-development plans, Good Clinical Practice, and good medical practice.
  • Serve as Medical Monitor for ongoing clinical studies, including reviewing eligibility criteria, safety data, adverse events, protocol deviations, and dose-escalation decisions.
  • Collaborate with Clinical Operations, Translational Medicine, Biometrics, Regulatory Affairs, Pharmacovigilance, contract research organizations, and external vendors to support high-quality study execution.
  • Provide medical-writing support to summarize clinical-trial data, including preparing study reports, integrated summaries, and clinical portions of package inserts and other product labeling.
  • Oversee adverse-event and safety-signal monitoring and reporting; ensure patient safety and ethical conduct of clinical trials; and develop and implement risk-management strategies.
  • Participate in Safety Review Committees, data-review discussions, and cross-functional development activities.
  • Analyze, interpret, and communicate emerging clinical, pharmacokinetic/pharmacodynamic, biomarker, and safety data to internal and external stakeholders.
  • Support regulatory interactions, including Investigational New Drug submissions, briefing documents, and responses to health-authority inquiries.
  • Develop and maintain relationships with investigators, key opinion leaders, advisory boards, and scientific experts.
  • Present clinical and scientific findings internally and externally, including at investigator meetings and scientific conferences.
  • Maintain awareness of scientific advancements, emerging therapies, and competitive developments in rheumatology, immunology, and inflammatory diseases.
  • Ensure studies are conducted in compliance with International Council for Harmonisation Good Clinical Practice guidelines, company standard operating procedures, and applicable regulatory requirements.

Desired Qualifications

  • Experience with or exposure to developing biologic therapies.
  • Previous regulatory-submission experience, such as New Drug Application or Biologics License Application submissions.
  • Clinical training, board certification, or board eligibility in rheumatology or a related specialty.
  • Experience with biologics, monoclonal antibodies, or immune-mediated inflammatory diseases.
  • Prior Medical Monitoring experience.
  • Experience supporting Investigational New Drug submissions and early regulatory interactions.
  • Experience working within small or emerging biotechnology companies.

About the Company

Avalo Therapeutics

Develops IL-1beta-targeting biologics for inflammation

Avalo Therapeutics develops biologic therapies that target the IL-1beta pathway for immune-mediated inflammatory diseases. Its lead candidate, abdakibart (AVTX-009), is a humanized monoclonal antibody that inhibits IL-1beta and blocks downstream inflammatory signaling, advancing toward a registrational Phase 3 program after positive Phase 2 results in hidradenitis suppurativa. AVTX-010 is a long-acting next-generation anti-IL-1beta antibody designed to extend dosing intervals. The company focuses on research and development of novel biologics with commercialization expected through pharmaceutical partnerships and product sales. Unlike some competitors that pursue broader or different inflammatory targets, Avalo concentrates specifically on IL-1beta–related inflammation with a pipeline aimed at improving dosing convenience and clinical outcomes in inflammatory diseases.

Company size
51-200
Company stage
IPO
Headquarters
Rockville, MD
Founded
2011

Recently Posted Jobs

Explore more opportunities at Avalo Therapeutics

See more jobs